Regulus Therapeutics (RGLS): Cutting PT to $10 - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Regulus Therapeutics (RGLS) PT Lowered to $9 at FBR
June 28, 2016 1:35 PM EDTFBR Capital analyst Christopher James lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) to $9.00 (from $30.00) following the FDA clinical hold on RG-101 but maintained a Buy rating.
James commented, "We are lowering our price target to $9 on shares of RGLS, following Regulus' announcement yesterday that the FDA has placed its... More
Regulus Therapeutics (RGLS) PT Cut to $13.50 at Chardan Capital Following Clinical Hold
June 28, 2016 7:38 AM EDTChardan Capital Markets analyst Madhu Kumar lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) 33% to $13.50 after the company announced the start of a clinical hold for RG-101 in the treatment of chronic hepatitis C virus (HCV).
Based upon the clinical hold, the firm now lowers their peak risk-adjusted RG-101 sales to $1.2 bn and NPV to $9.24... More
